Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Non Operating Income (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Non Operating Income for 4 consecutive years, with $881000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 2.44% to $881000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 4.78% decrease, with the full-year FY2025 number at $6.0 million, down 17.41% from a year prior.
  • Non Operating Income was $881000.0 for Q4 2025 at TScan Therapeutics, down from $903000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.7 million in Q3 2024 to a low of -$74000.0 in Q4 2022.
  • A 4-year average of $989076.9 and a median of $881000.0 in 2025 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 2471.43% in 2023, then tumbled 48.22% in 2024.
  • TScan Therapeutics' Non Operating Income stood at -$74000.0 in 2022, then surged by 2456.76% to $1.7 million in 2023, then crashed by 48.22% to $903000.0 in 2024, then decreased by 2.44% to $881000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Non Operating Income are $881000.0 (Q4 2025), $903000.0 (Q4 2024), and $2.7 million (Q3 2024).